Capital & markets
AI funding tracker
Explore AI financing records, deal terms and the evidence behind them.
Funding over time
Series B funding activity
Jul 2026 – 5 Nov 2026 Current month incomplete
Scroll horizontally to view every month →
Where funding flows
Recipient-company country · Jul 2026 – 5 Nov 2026
Country totals use current company headquarters or registered country, where sourced. They do not locate project spending or investor origin. Unknown locations are excluded from the map.
Larger dots = larger disclosed country totals. Area scales with value; very small totals use a minimum visible dot. Red outlined dots indicate undisclosed amounts.
Select a dot or country to see the companies behind it.
United Kingdom $2.3B · 2 deals
2 deals with recorded USD amounts; 0 without. 2 company profiles.
- Olix ↗$312M · 1 dealsProfile headquarters · Checked 2026-11-04
- Isomorphic Labs ↗$2B · 1 dealsHeadquarters · Location source ↗ · Checked 2026-10-29
Finland $189M · 1 deals
1 deals with recorded USD amounts; 0 without. 1 company profiles.
- Verda ↗$189M · 1 dealsProfile headquarters · Checked 2026-11-04
Country-level markers are approximate. Geography: Natural Earth. Boundaries imply no position on sovereignty. Location coverage is incomplete; totals reflect tracked records, not the whole market.
Tracked records, not total market funding. 58 of 58 dates are estimated from coverage. Months without records do not mean zero market activity.
Monthly figures & methodology
This view includes only the selected record type. The stage and company-confirmed filters apply to both the chart and the ledger; selecting a month filters the ledger only. Company confirmation is not an independent audit.
The chart starts with the first month containing deals within the last 12 calendar months. Later months remain visible, including gaps. The amount line has a gap wherever no usable USD amounts are recorded. Months with deals but no usable USD amounts show a light grey bar at a fixed 80% of chart height, labelled with the number of deals without an amount; this indicator does not represent a monetary value. Months without deals have no grey bar. Calendar months are grouped by recorded announcement date; estimated dates use the source-coverage date. Current-month figures run through 5 Nov 2026 (UTC). Future dates and 0 undated records are excluded. Only positive recorded USD amounts are summed; unavailable amounts are not treated as zero. Merged duplicates and records held for quality review are excluded. Values reflect the stored dataset and may include announced commitments rather than completed transactions.
| Month | Recorded value · USD | Deals | With amount | Without amount | Estimated dates |
|---|---|---|---|---|---|
| July 2026 | $682,000,000 | 3 | 3 | 0 | 3 |
| August 2026 | $4,601,826,000 | 16 | 16 | 0 | 16 |
| September 2026 | $4,713,200,000 | 17 | 16 | 1 | 17 |
| October 2026 | $2,183,000,000 | 21 | 20 | 1 | 21 |
| November 2026 (to date) | $75,000,000 | 1 | 1 | 0 | 1 |
Dataset coverage · 790 records
Our observed dataset, not a complete measure of the AI market. Categories overlap. Company confirmation does not constitute an independent financial audit.
Funding records
Watch companies & export ↗| Company | Amount / stage | Recorded date | Evidence status | Source |
|---|---|---|---|---|
| Kalepa ↗ | $75M Series B | 5 Nov 2026 Estimated date | Reported | Evidence ↗ |
| Collective ↗ | $100M Series B | 29 Oct 2026 Estimated date | Reported | Evidence ↗ |
| Infisical ↗ | $40M Series B | 28 Oct 2026 Estimated date | Reported | Evidence ↗ |
| Casap ↗ | $56 million Series B | 28 Oct 2026 Estimated date | Reported | Evidence ↗ |
| Tandem Health ↗ | Undisclosed Series B | 27 Oct 2026 Estimated date | Reported | Evidence ↗ |
| Simplismart ↗ | $14 million Series B | 27 Oct 2026 Estimated date | Reported | Evidence ↗ |
| Nevis ↗ | $70 million Series B | 26 Oct 2026 Estimated date | Reported | Evidence ↗ |
| Legora ↗ | $550 million Series B | 21 Oct 2026 Estimated date | Reported | Evidence ↗ |
| Daytona ↗ | $60 million Series B | 20 Oct 2026 Estimated date | Reported | Evidence ↗ |
| Town.com Inc. ↗ | $108M Series B | 20 Oct 2026 Estimated date | Reported | Evidence ↗ |
| Town ↗ | $108 million Series B | 19 Oct 2026 Estimated date | Reported | Evidence ↗ |
| RapidCanvas Inc. ↗ | $29M Series B | 16 Oct 2026 Estimated date | Reported | Evidence ↗ |
| RapidCanvas ↗ | $29M Series B | 16 Oct 2026 Estimated date | Reported | Evidence ↗ |
| RapidCanvas Inc ↗ | $29M Series B | 16 Oct 2026 Estimated date | Reported | Evidence ↗ |
| Harmonic Security ↗ | $50 million Series B | 14 Oct 2026 Estimated date | Reported | Evidence ↗ |
| Scarlet ↗ | $50 million Series B | 12 Oct 2026 Estimated date | Reported | Evidence ↗ |
| Arena ↗ | $200 million Series B | 8 Oct 2026 Estimated date | Reported | Evidence ↗ |
| Nous Research ↗ | $90 million Series B | 7 Oct 2026 Estimated date | Reported | Evidence ↗ |
| Stuut ↗ | $52.5M Series B | 7 Oct 2026 Estimated date | Reported | Evidence ↗ |
| Vinci4D Inc. ↗ | $250 million Series B | 6 Oct 2026 Estimated date | Reported | Evidence ↗ |
| Namespace ↗ | $42M Series B | 5 Oct 2026 Estimated date | Reported | Evidence ↗ |
| Armadin ↗ | $255.5M Series B | 2 Oct 2026 Estimated date | Reported | Evidence ↗ |
| Flow Engineering ↗ | $50 million Series B | 30 Sep 2026 Estimated date | Reported | Evidence ↗ |
| Efficient Computer ↗ | $97M Series B | 30 Sep 2026 Estimated date | Reported | Evidence ↗ |
| Ema ↗ | $77 million Series B | 23 Sep 2026 Estimated date | Reported | Evidence ↗ |
| Ema Unlimited Inc. ↗ | $77M Series B | 23 Sep 2026 Estimated date | Reported | Evidence ↗ |
| Firecrawl Inc. ↗ | $75M Series B | 22 Sep 2026 Estimated date | Reported | Evidence ↗ |
| Verda ↗ | $189 million Series B | 22 Sep 2026 Estimated date | Reported | Evidence ↗ |
| Morphotonics ↗ | €40M+ Series B | 22 Sep 2026 Estimated date | Reported | Evidence ↗ |
| Arcee AI ↗ | $20 million Series B | 16 Sep 2026 Estimated date | Reported | Evidence ↗ |
Amounts and dates remain as recorded. No missing amount is treated as zero. Merged duplicates and records held for quality review are excluded. Read the methodology.
The investor’s perspective
Before the valuation, check the evidence.
Read our framework for interpreting a financing event and building an investment shortlist.